Особенности иммунного статуса женщин в постменопаузальном периоде с климактерическим синдромом и фиброзно-кистозной мастопатией на фоне заместительной гормональной терапии
И К Богатова, N. Yu. Sotnikova, И. А. Васильева et al. · Bulletin of the Ivanovo State Medical Academy · 2011
Immune status indices in women with climacteric syndrome and fibrous-cystic disease of mammary glands after hormone replacement therapy with administration of Femoston l/5 and Klimodien were studied. It was stated that the concomitant fibrous-cystic disease of mammary glands irrеsресtivе of climacteric syndrome presence or absence was accompanied by the increased level of monocytes with intracellular IL-6 production. Hormone replacement therapy led to the decrease of the activated monocytes amount. Femoston 1/5 additionally led to the diminishment of the content of peripheral monocytes with intracellular IL-6 production. It allowed to recommend to administer Femoston for the treatment of the climacteric syndrome in these patients.
Cited by 0 works.